secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001641172-25-018808
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Calidi shareholders approve reverse stock split and 3M-share equity plan increase
--------------------------------------------------------------------------------

- Elected James Schoeneck (6.5M for) and George Peoples (6.6M for) as Class II directors.
- Ratified CBIZ CPAs P.C. as auditor for FY2025 (15.6M for, 1.3M against).
- Approved reverse stock split ratio of 1:2 to 1:19, with board discretion on exact ratio.
- Approved amendment to 2023 Equity Plan increasing authorized shares from 393,780 to 3,393,780.
- All four proposals passed; quorum of 53.26% of shares represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225018808/0001641172-25-018808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225018808/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer